{
    "clinical_study": {
        "@rank": "132902", 
        "arm_group": [
            {
                "arm_group_label": "ondansetron-betahistine", 
                "arm_group_type": "Experimental", 
                "description": "ondansetron-betahistine group"
            }, 
            {
                "arm_group_label": "ondansetron", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ondansetron group"
            }
        ], 
        "brief_summary": {
            "textblock": "Many patients undergoing gynecologic laparoscopic surgery experience postoperative nausea\n      and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists such as\n      ondansetron. Involvement of multiple types of receptors and factors may be a reason for\n      inadequate control of PONV with a single agent. Betahistine, a histamine antagonist at H1\n      receptor and antagonist at H3 receptor, is widely used as a treatment of dizziness.\n      Dizziness is one of the cause of nausea and vomiting. This study is to compare the effects\n      of ondansetron and combined ondansetron and betahistine in preventing PONV in high-risk\n      patients receiving intravenous opioid-based patient-controlled analgesia (IV-PCA) after\n      gynecological laparoscopic surgery."
        }, 
        "brief_title": "Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nausea and Vomiting", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting", 
                "Postoperative Nausea and Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient scheduled for elective gynecological laparoscopic surgery\n\n          -  American society of Anesthesiologists physical class I, \u2161, between the ages of 20 and\n             70 years\n\n        Exclusion Criteria:\n\n          -  hepatorenal disease\n\n          -  BMI > 35 kg/m2\n\n          -  allergy to ondansetron or betahistine\n\n          -  gastrointestinal disease\n\n          -  vomiting within 24h\n\n          -  administration of antiemetics or opioids within 24h\n\n          -  QT prolongation (QTc > 440ms)\n\n          -  Pheochromocytoma\n\n          -  pregnant\n\n          -  problem with communication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02026778", 
            "org_study_id": "4-2013-0691"
        }, 
        "intervention": [
            {
                "arm_group_label": "ondansetron", 
                "description": "The ondansetron group is given placebo (pyridoxin) instead of betahistine.\nThe ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.", 
                "intervention_name": "ondansetron", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ondansetron-betahistine", 
                "description": "The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.\nThe ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA.", 
                "intervention_name": "ondansetron-betahistine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Betahistine", 
                "Ondansetron"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "koobn@yuhs.ac", 
                "last_name": "Bon Nyeo Koo, MD", 
                "phone": "82-2-2227-7897"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "koobn@yuhs.ac", 
            "last_name": "Bon Nyeo Koo, MD", 
            "phone": "82-2-2228-2420"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "evaluation of nausea and vomiting with verbal rating scale (VRS, 0, no nausea; 10, worst imaginable nausea)", 
            "measure": "postoperative nausea and vomiting", 
            "safety_issue": "No", 
            "time_frame": "at postoperative 24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02026778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}